Pilot deployment of a machine-learning enhanced prediction of need for hemorrhage resuscitation after trauma - the ShockMatrix pilot study.
Source check: Source checked. Not independent scientific confirmation.
Finding: Traumabase development cohort 28,614, NHR 11%; XGBoost F4 .76 [0.73,.78]; prospective app phase measured feasibility and compared clinician/model likelihood ratios, but article says it was not intended to assess model performance because underpowered. Methods/Results: Traumabase development cohort 28,614, NHR 11%; XGBoost F4 .76 [0.73,.78]; prospective app phase measured feasibility and compared clinician/model likelihood ratios, but article says it was not intended to assess model performance because underpowered. Testing: Methods/Results: Traumabase development cohort 28,614, NHR 11%; XGBoost F4 .76 [0.73,.78]; prospective app phase measured feasibility and compared clinician/model likelihood ratios, but article says it was not intended to assess model performance because underpowered.. XGBoost on nine prehospital predictors produced a defined NHR model and a real-time multicenter feasibility pilot; the pilot was explicitly underpowered to assess model performance. Source affiliation was not stated in the reviewed case checks and was unavailable in the local bibliographic cache.
Technology: Traumabase development cohort 28,614, NHR 11%; XGBoost F4 .76 [0.73,.78]; prospective app phase measured feasibility and compared clinician/model likelihood ratios, but article says it was not intended to assess model performance because underpowered.
Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.
- AI contribution
- Traumabase development cohort 28,614, NHR 11%; XGBoost F4 .76 [0.73,.78]; prospective app phase measured feasibility and compared clinician/model likelihood ratios, but article says it was not intended to assess model performance because underpowered.
- Test and result
- Traumabase development cohort 28,614, NHR 11%; XGBoost F4 .76 [0.73,.78]; prospective app phase measured feasibility and compared clinician/model likelihood ratios, but article says it was not intended to assess model performance because underpowered.
- Limitation / still unknown
- Generalizability beyond the reported study population, data, and protocol was not established in the reviewed material.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1186/s12911-024-02723-9
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.